BioNxt Solutions Inc. (CSE:BNXT)
0.465
+0.015 (3.33%)
Apr 28, 2026, 3:49 PM EST
BioNxt Solutions Revenue
BioNxt Solutions had revenue of 11.26K CAD in the quarter ending September 30, 2025, a decrease of -34.17%. This brings the company's revenue in the last twelve months to 15.82K, down -62.34% year-over-year. In the year 2024, BioNxt Solutions had annual revenue of 26.99K, down -92.75%.
Revenue (ttm)
15.82K
Revenue Growth
-62.34%
P/S Ratio
3,809.15
Revenue / Employee
n/a
Employees
n/a
Market Cap
60.27M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Planet 13 Holdings | 141.74M |
| Vext Science | 66.63M |
| Leef Brands | 47.70M |
| Decibel Cannabis Company | 112.72M |
| LSL Pharma Group | 26.80M |
| C21 Investments | 45.62M |
| ZYUS Life Sciences | 465.00K |
| Rubicon Organics | 59.45M |
BioNxt Solutions News
- 19 hours ago - BioNxt Solutions Inc.: BioNxt Applies Advanced Drug Delivery Strategy and Psychedelic Compound Library to Emerging Therapeutics Market Amid Accelerating Global Momentum - Finanz Nachrichten
- 19 hours ago - BioNxt Applies Advanced Drug Delivery Strategy and Psychedelic Compound Library to Emerging Therapeutics Market Amid Accelerating Global Momentum - Wallstreet:Online
- 19 hours ago - BioNxt Applies Advanced Drug Delivery Strategy and Psychedelic Compound Library to Emerging Therapeutics Market Amid Accelerating Global Momentum - Accesswire
- 14 days ago - BioNxt Solutions Inc.: BioNxt Initiates GMP Manufacturing of Clinical-Grade Sublingual Cladribine Film Targeting Multiple Sclerosis - Finanz Nachrichten
- 14 days ago - BioNxt Initiates GMP Manufacturing of Clinical-Grade Sublingual Cladribine Film Targeting Multiple Sclerosis (MS) - Accesswire
- 14 days ago - BioNxt Initiates GMP Manufacturing of Clinical-Grade Sublingual Cladribine Film Targeting Multiple Sclerosis (MS) - Wallstreet:Online
- 21 days ago - BioNxt Solutions Inc.: BioNxt Secures Unitary European Patent for Sublingual Cladribine ODF Platform Across 18 Countries - Finanz Nachrichten
- 21 days ago - BioNxt Secures Unitary European Patent for Sublingual Cladribine ODF Platform Across 18 Countries - Accesswire